Actis Buys $48 Million Stake In Symbiotec Pharmalab
This article was originally published in PharmAsia News
Executive Summary
Symbiotec Pharmalab has sold a $48 million stake in the India-based company to Actis, an international private-equity firm that specializes in emerging markets.